Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR014 in first-line advanced non-small cell lung cancer
2008-002703-20Phase 2Completed
- Sponsor
- MolMed
- Start
- May 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of NGR-TNF in non-small cell lung cancer (NSCLC) (2 arms), sponsored by MolMed. Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
NGR-TNF
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-002703-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002703-20.